Anti-tumor responses induced by chemokine CCL19 transfected into an ovarian carcinoma model via fiber-mutant adenovirus vector

Biol Pharm Bull. 2005 Jun;28(6):1066-70. doi: 10.1248/bpb.28.1066.


Considerable attention has recently been paid to the application of chemokines to cancer immunotherapy because of their chemotactic affinity for a variety of immune cells and because several chemokines are strongly angiostatic. In the present study, the recombinant adenovirus vectors encoding chemokine CCL19 or XCL1 in an E1 cassette (AdRGD-mCCL19 and AdRGD-mXCL1) were developed. The constructed fiber-mutant adenovirus vector, which contained the integrin-targeting Arg-Gly-Asp (RGD) sequence in the fiber knob, notably enhanced the transfection efficiency to OV-HM ovarian carcinoma cells compared to that induced by conventional adenovirus vector. The results of an in vitro chemotaxis assay for chemokine-encoding vector demonstrated that both AdRGD-mCCL19 and AdRGD-mXCL1 could induce the migration of cells expressing specific chemokine receptors. Of the two chemokine-encoding vectors evaluated in vivo, AdRGD-mCCL19 showed significant tumor-suppressive activity in B6C3F1 mice via transduction into OV-HM cells, whereas XCL1 did not exhibit any notable anti-tumor effects, suggesting that CCL19 may be a candidate for cancer immunotherapy.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / genetics*
  • Animals
  • Antineoplastic Agents* / administration & dosage
  • Cell Line, Tumor
  • Chemokine CCL19
  • Chemokines, CC / administration & dosage
  • Chemokines, CC / genetics*
  • Female
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / genetics*
  • Humans
  • Mice
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / genetics*
  • Transfection / methods*


  • Antineoplastic Agents
  • CCL19 protein, human
  • Ccl19 protein, mouse
  • Chemokine CCL19
  • Chemokines, CC